Table 3. Survival analysis considering key clinical and pathological features.

Clinical features	Progression-free survival			Overall survival
	Number of recurrence or disease progression/total	HR (95% CI)	p value	Number of deaths/total	HR (95% CI)	p value
FIGO staging
FIGO I+II	6 / 29	Reference		7/29	Reference
FIGO III+IV	52 / 77	4.87 (2.08–11.38)	<0.001	50/77	3.48 (1.57–7.71)	0.002
Post-surgery residual disease
No	20 / 57	Reference		20/57	Reference
Yes	38 / 49	3.39 (1.96–5.88)	<0.001	37/49	2.58 (1.49–4.45)	0.001
Histological grade
Low histological grade	5 / 21	Reference		5/21	Reference
High histological grade	53 / 85	3.62 (1.44–9.09)	0.006	52/85	2.95 (1.17–7.41)	0.02
WT1 expression
Negative (complete absence to <1%)	24 / 42	Reference		27/42	Reference
Positive (≥1%)	33 / 63	1.19 (0.70–2.01)	0.51	29/63	1.45 (0.86–2.46)	0.16
IHC p53/p16 index
Low-grade pattern (p53 staining in ≥1% and <70% and/or p53 complete absence + p16 <90%)	10/29	Reference		9/29	Reference
High-grade pattern (p53 ≥70% or p53 complete absence + p16 ≥90%)	48/76	2.19 (1.10–4.34)	0.02	47/76	1.99 (0.98–4.08)	0.05

FIGO: The International Federation of Gynecology and Obstetrics; PFS: progression-free survival; OS: overall survival; CI: Confidence interval; HR: Hazard ratio; statistically significant differences are indicated in bold. In the multivariate analysis, FIGO staging and histological grade were significantly associated with PFS; FIGO III + IV had an HR = 2.87 (95% CI: 1.15–7.18) and presence of post-surgery residual disease had an HR = 2.04 (1.12–3.71) and were more likely to progress compared with FIGO I + II and absence of post-surgery residual disease. There was a trend association between FIGO staging (HR = 2.28; 95% CI: 0.96–5.39; p = 0.06) and post-surgery residual disease (HR = 1.73; 95% CI: 0.96–3.13; p = 0.06) with OS in a multivariate model.